Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
People with HIV/HCV co-infection see good cure rates in real-world practice in Madrid

More than 90% of HIV-positive people treated with direct-acting antivirals for hepatitis C – including many with liver cirrhosis – achieved sustained virological response and few discontinued treatment

Published
23 November 2016
By
Liz Highleyman
8-week triple DAA combo cures most people with genotype 1-6 hepatitis C

A three-drug regimen of sofosbuvir, velpatasvir and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated people with all

Published
21 November 2016
By
Liz Highleyman
Birth cohort screening and linkage to care for HCV treatment still weak in United States

Grave weaknesses in hepatitis C screening and linkage to care are still widespread in the United States and threaten to leave a large proportion of baby boomers

Published
18 November 2016
By
Keith Alcorn
AbbVie pangenotypic combination cures 98% or above across genotypes

AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in three large clinical trials covering five out of six genotypes

Published
16 November 2016
By
Keith Alcorn
AbbVie pangenotypic combination cures almost all hard-to-treat people with HCV genotype 3

AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 patients – those with cirrhosis and/or previous treatment experience – in a

Published
16 November 2016
By
Keith Alcorn
US Veterans Affairs and Australia show potential for rapid elimination of hepatitis C

If sufficient money is available to pay for direct-acting antivirals (DAAs), the US Veterans Affairs (VA) could cure the majority of veterans under its care of hepatitis

Published
15 November 2016
By
Keith Alcorn
Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones

Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss,

Published
15 November 2016
By
Liz Highleyman
Grazoprevir/elbasvir + sofosbuvir highly effective for hard-to-treat genotype 3 hepatitis C patients

A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV) genotype

Published
14 November 2016
By
Liz Highleyman
Where hepatitis C rates are seven times the US average — and a cure is kept out of reach

With the opioid epidemic steamrolling through Appalachia, the new face of hepatitis C is increasingly young, white, and rural. In Kentucky, a state beset by hepatitis C rates seven times the national average, Harvoni and other new hepatitis C drugs remain largely out of reach.

Published
14 November 2016
From
STAT
Liver cancer risk reduced after hepatitis C treatment, but vigilance needed for aggressive cancers in months after treatment

People who are cured of hepatitis C after a course of direct-acting antiviral (DAA) treatment do not have a higher risk of developing liver cancer (hepatocellular carcinoma),

Published
14 November 2016
By
Keith Alcorn

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.